VANCOUVER, British Columbia – TheNewswire – June 19, 2020 — Naturally Splendid Enterprises Ltd. (“Naturally Splendid”)
(TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) provides the followingupdate in regards to the Phase 2 Clinical Trial Application with Health Canada for a potential COVID-19 treatment. As an update to the Clinical Trial Application (CTA) process with Health Canada: A CTA was approved for submission to Health Canada on May 17, 2020. The Health Canada drug directoratesubsequently moved the application down the appropriate path for review and with this requested more information be submitted to accompany this original application. In response, a set ofaddendum documents were submitted to meet the request for more data on June 1-2, 2020. Additional documentation was requested, once again, by Health Canada to add to the application andthis additional set was submitted June 15, 2020 to meet the data demand. We are encouraged by the communication and facilitation support by Health Canada and anticipates more direction byHealth Canada shortly.